GoPro, Nutanix, SCYNEXIS Downgraded

Shares of GoPro, Nutanix, and SCYNEXIS are struggling after receiving bearish analyst attention

Mar 3, 2017 at 10:10 AM
facebook twitter linkedin

Analysts are weighing in on camera enthusiast GoPro Inc (NASDAQ:GPRO), cloud stock Nutanix Inc (NASDAQ:NTNX), and biotech issue SCYNEXIS Inc (NASDAQ:SCYX). Here's a quick roundup of today's bearish brokerage notes on GPRO, NTNX, and SCYX shares.

Fresh "Sell" Rating Weighs On GoPro Stock

GPRO shares are down 2% in early trading at $9.08, after Citigroup started coverage on the stock with a "sell" rating and an $8 price target. Moreover, the brokerage firm described the company's position within the standalone imaging market as the "best house in a deteriorating neighborhood." It's been a horrible few months for the equity, which has fallen from an early October peak of $17.68, hit hard by a disappointing earnings report last month. Short sellers have to be loving it, though. Short interest on GoPro Inc accounts for more than one-fifth of its total float. 

Analysts Punish Nutanix After Forecast Disappoints

NTNX is getting crushed, down 20.8% at $24.64 and short-sale restricted (SSR), due to a softer-than-expected current-quarter forecast. Morgan Stanley downgraded the stock to "underweight" from "equal weight," and was among the six brokerage firms to lower their price targets, eyeing a move to $20 -- record-low territory. Nutanix Inc peaked at $46.78 back in October on its second day of trading, so it's been a rough ride for shareholders. Still, almost half of the analysts tracking the stock recommend buying it, and only one suggests selling the shares. 

FDA Decision Rattles SCYNEXIS Shares

SCYX has given back 20% to trade at $2.62, finding a spot on the SSR list, after the Food and Drug Administration (FDA) put a clinical hold on new studies of the company's experimental treatment for fungal infections. RBC subsequently responded with a price-target cut to $11 from $15. Still, this is double the stock's annual high of $5.51, and most of Wall Street is, for now, behind SCYNEXIS Inc. Specifically, all four covering analysts recommend buying the shares. Looking ahead, the company will report earnings on Monday morning.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners